Breaking Finance News

Zacks Investment Research covered Advanced Accelerator Application SA(ADR) (NASDAQ:AAAP), raising its price target to $44.00 earlier today

In a report released on 10/11/2016 Zacks Investment Research raised the target price of Advanced Accelerator Application SA(ADR) (NASDAQ:AAAP) to $44.00 stating a potential upside of 0.16%.

On 3/16/2016, Citigroup reported on Advanced Accelerator Application SA(ADR) (NASDAQ:AAAP) bumped up the target price from $32.00 to $36.00. At the time, this suggested an upside of 0.05%.

Having a price of $38.01, Advanced Accelerator Application SA(ADR) (NASDAQ:AAAP) traded -2.21% lower on the day. The last stock price is up 15.69% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the date range. Advanced Accelerator Application SA(ADR) has recorded a 50-day average of $36.18 and a 200-day moving average of $32.85. 108,894 shares of the stock traded hands, up from an average trading volume of 91,905

Performance Chart

Advanced Accelerator Application SA(ADR) (NASDAQ:AAAP)

Advanced Accelerator Application SA(ADR) has a 52 week low of $18.00 and a 52 week high of $39.66 Advanced Accelerator Application SA(ADR)’s market capitalization is presently $0.

A total of 4 brokers have issued a report on the stock. Two firms rating the stock a strong buy, 1 analyst rating the company a buy, one broker rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 firms rating the company a sell with a one year target of $34.51.

Brief Synopsis About Advanced Accelerator Application SA(ADR) (NASDAQ:AAAP)

Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer. It is engaged in developing its therapeutic candidate, Lutathera, which is a compound for the treatment of neuro endocrine tumors (NETs). It has a portfolio of approximately six diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. PET and SPECT are imaging techniques in molecular nuclear diagnostics (MND) with applications in clinical oncology, cardiology and neurology. Its products in clinical development include Lutathera, Somakit and Annexin V-128. Its commercial products include Gluscan/Gluscan 500/Barnascan, IASOflu, IASOdopa, DOPAVIEW, IASOcholine, AAACholine, MIBITEC/Adamibi and Leukokit.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.